ALAMEDA, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Xenogen Corporation
(Nasdaq: XGEN) announced today an extension of its licensing agreement with
Novartis (NYSE: NVS) for up to two more years.
Novartis will continue to license Xenogen's proprietary software (Living
Image(R) Software) and patented methods of biophotonic imaging for use with
Xenogen's biophotonic imaging systems (IVIS(R) Imaging Systems). The
technology will be used for research in several therapeutic areas at Novartis
research sites in the United States, Japan and Switzerland. This is an
extension of the original agreement between the two companies that was signed
in 2000.
Xenogen's technologies are designed to enable researchers to visualize and
track biological processes in living animals, non-invasively and in real time.
The technology helps researchers analyze gene function and follow the spread
of disease or effects of a drug candidate throughout the system. The result
is more accurate, predictable data that can improve the success rate of
pre-clinical drug development, saving both time and money.
"We are delighted that Novartis has extended its license agreement to use
Xenogen's technology for drug discovery and development," said Pamela R.
Contag, Ph.D., president of Xenogen Corporation. "We believe the extension of
our license agreement with one of the world's leading pharmaceutical companies
validates Xenogen's biophotonic imaging technology in expediting drug
discovery and development."
About Xenogen Corporation
Xenogen Corporation is a leading biotechnology company offering an
integrated suite of biophotonic real-time in vivo imaging and genetic
modification technologies that can help expedite drug discovery and
development, and significantly reduce the cost and time to market for new
therapies. Xenogen's VivoVision(TM) Systems non-invasively illuminate and
monitor biological processes within living mammals, at the molecular level, in
real time. The technology is designed to provide higher quality in vivo data
earlier in the drug discovery and development process. VivoVision(TM)
Solutions are designed to improve discovery and pre-clinical research in
multiple therapeutic areas. VivoVision(TM) Biosciences represents more than
15 years of experience in the creation and characterization of animal models,
including genetic modifications, comprehensive phenotyping, compound profiling
and custom design and production of light producing cells, microorganisms and
animals.
More information is available at http://www.xenogen.com. Xenogen(R), Living
Image(R), VivoVision(TM) and IVIS(R) are trademarks of Xenogen Corporation.
Forward-Looking Statements
This press release contains forward-looking statements regarding the
performance and intended uses of our imaging products and technologies. These
forward-looking statements are based on our current expectations, estimates
and assumptions and are subject to many risks, uncertainties and unknown
future events that could cause actual results to differ materially. Actual
performance and results of imaging products and technologies may differ
materially from those set forth in this release due to the risks and
uncertainties inherent in our business, including, without limitation: our
ability to continue to deliver our products on a timely basis to meet customer
demand; our ability to enforce our intellectual property rights or operate
without infringing or misappropriating the proprietary rights of others;
products, services or technologies introduced by competing companies; and
other risk factors set forth in our filings with the Securities and Exchange
Commission. For a discussion of these and other factors that could impact the
adoption, performance or use of our imaging products and technologies and
cause them to differ materially from those in the forward-looking statements,
please refer to our recent filings with the Securities and Exchange
Commission, including our most recent quarterly report on Form 10-Q for the
quarter ended September 30, 2005. We assume no obligation to update any
forward-looking statements or information, which speak as of their respective
dates.
Available Topic Expert(s): For information on the listed expert(s), click
appropriate link.
Pamela R. Contag, Ph.D.
http://profnet.prnewswire.com/ud_public.jsp?userid=513625
David W. Carter
http://profnet.prnewswire.com/ud_public.jsp?userid=513851
SOURCE Xenogen Corporation
 back to top
Related links:
http://www.xenogen.com
CONTACT:
investors, William A. Albright of Xenogen
Corporation, +1-510-291-6104; or media, Stephanie Scherbak of
Manning Selvage & Lee, +1-415-278-3326, for Xenogen Corporation
|
